Key regions: Japan, Italy, China, South Korea, Brazil
The COVID-19 Vaccines market in El Salvador has been developing at a steady pace in recent months.
Customer preferences: El Salvador is a small country in Central America with a population of approximately 6.5 million people. The country has been struggling with the COVID-19 pandemic, with a high number of cases and deaths. As a result, there is a high demand for COVID-19 vaccines in the country. The government has been working to secure vaccines from different sources, and there is a growing interest among the population to get vaccinated.
Trends in the market: The COVID-19 vaccines market in El Salvador has been growing steadily in recent months. The country has received vaccines from different sources, including the COVAX facility, the United States, and China. The government has been working to distribute the vaccines to different parts of the country, with a focus on vulnerable populations. There is also a growing interest among the population to get vaccinated, with many people signing up for vaccination appointments.
Local special circumstances: El Salvador has been facing a number of challenges in its efforts to combat the COVID-19 pandemic. The country has a weak healthcare system, with limited resources and infrastructure. There is also a high level of poverty and inequality, which has made it difficult for many people to access healthcare services. In addition, there is a high level of crime and violence in the country, which has further complicated the government's efforts to distribute vaccines.
Underlying macroeconomic factors: El Salvador is a small and open economy that is heavily dependent on exports, remittances, and foreign investment. The country has been facing a number of challenges in recent years, including high levels of debt, political instability, and social unrest. The COVID-19 pandemic has further exacerbated these challenges, with the country experiencing a sharp contraction in economic activity in 2020. The government has been working to implement a number of policies to support the economy, including fiscal stimulus measures and financial assistance to affected businesses. However, the country's economic recovery is likely to be slow and uneven, with many challenges still to be overcome.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
